Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 3.95 -6.18% -0.26
BCRX closed down 0.47 percent on Wednesday, August 5, 2020, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical BCRX trend table...

Date Alert Name Type % Chg
Earnings Movers Other -6.18%
Wide Bands Range Expansion -6.18%
Oversold Stochastic Weakness -6.18%
Earnings Movers Other -6.62%
Wide Bands Range Expansion -6.62%
Oversold Stochastic Weakness -6.62%
Stochastic Buy Signal Bullish -10.23%
Pocket Pivot Bullish Swing Setup -10.23%
Wide Bands Range Expansion -10.23%
Oversold Stochastic Weakness -10.23%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Chemistry Biotechnology Diseases Chemical Compounds Coronavirus Enzymes Gout Seasonal Influenza Acetamides Drug Design

Is BCRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.2862
52 Week Low 1.38
Average Volume 7,492,896
200-Day Moving Average 3.34
50-Day Moving Average 4.62
20-Day Moving Average 4.73
10-Day Moving Average 4.33
Average True Range 0.32
ADX 15.76
+DI 18.22
-DI 24.53
Chandelier Exit (Long, 3 ATRs ) 5.07
Chandelier Exit (Short, 3 ATRs ) 4.98
Upper Bollinger Band 5.61
Lower Bollinger Band 3.85
Percent B (%b) 0.21
BandWidth 37.30
MACD Line -0.16
MACD Signal Line -0.08
MACD Histogram -0.0778
Fundamentals Value
Market Cap 338.6 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -6.79
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.55
Resistance 3 (R3) 4.55 4.43 4.49
Resistance 2 (R2) 4.43 4.35 4.43 4.48
Resistance 1 (R1) 4.32 4.29 4.26 4.32 4.46
Pivot Point 4.21 4.21 4.18 4.21 4.21
Support 1 (S1) 4.09 4.12 4.04 4.10 3.96
Support 2 (S2) 3.98 4.07 3.98 3.94
Support 3 (S3) 3.87 3.98 3.93
Support 4 (S4) 3.87